Loading…
Moleculin Biotech, Inc. is projected to rise to $0.5578 by 2027, a +31% move from its current price of $0.425. MBRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.3788 | $0.4251 | $0.477 | +0.01% |
| Aug 6 | $0.3611 | $0.4251 | $0.5004 | +0.02% |
| Aug 7 | $0.3482 | $0.4252 | $0.5192 | +0.04% |
| Aug 8 | $0.3376 | $0.4252 | $0.5355 | +0.05% |
| Aug 9 | $0.3286 | $0.4253 | $0.5504 | +0.06% |
| Aug 10 | $0.3206 | $0.4253 | $0.5642 | +0.07% |
| Aug 11 | $0.3135 | $0.4254 | $0.5771 | +0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3135 | $0.4254 | $0.5771 | +0.09% |
| Week 2 | $0.2765 | $0.4257 | $0.6555 | +0.17% |
| Week 3 | $0.2512 | $0.4261 | $0.7228 | +0.26% |
| Week 4 | $0.2317 | $0.4265 | $0.7851 | +0.34% |
| Week 5 | $0.2157 | $0.4268 | $0.8445 | +0.43% |
| Week 6 | $0.2023 | $0.4272 | $0.902 | +0.52% |
| Week 7 | $0.1907 | $0.4276 | $0.9585 | +0.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Moleculin Biotech, Inc. is a late-stage pharmaceutical development company that focuses on therapies for tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
MBRX is Moleculin Biotech, Inc., a small-cap healthcare company trading under the ticker MBRX. The current price is $0.40 with a market cap of $2.83M and a rank of 5395. The stock sits in the Healthcare sector and carries a volatile, micro-cap profile given its tiny capitalization.
The year-by-year forecast shows a mix of neutral and bullish outcomes, with the average price path advancing from $0.40 in 2026 to $1.21 in 2050 and with upside potential reflected in several years. Key averages span from $0.40 in 2026 to $1.21 in 2050, with max prices reaching as high as $2.78 by 2050 and notable mid-range gains along the way; overall ROI across the horizon ranges from 0% to 201.8%.
A major floor 5.9% below — a decisive break under it would weaken the trend.
The nearest floor, 5.9% below — buyers have tended to step in here.
The nearest ceiling, 740.0% above — a clean break opens room to run.
A major ceiling 988.6% above — clearing it would confirm fresh momentum.
Key MBRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MBRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.43 | Sell | $1.20 | Sell |
| MA 10 | $1.78 | Sell | $1.59 | Sell |
| MA 20 | $2.03 | Sell | $1.94 | Sell |
| MA 50 | $2.43 | Sell | $2.29 | Sell |
| MA 100 | $2.39 | Sell | $2.89 | Sell |
| MA 200 | $4.46 | Sell | $6.67 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 16.29 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -328.25 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.16 | Sell |
| ROC (12) | -82.68 | Sell |
| Bollinger %B (20,2) | -0.32 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.18 | Sell |
| Awesome (5,34) | -0.95 | Sell |
| Ultimate (7,14,28) | 9.81 | Buy |
| Momentum (10) | -1.70 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 0.89 | Sell |
| ADX (14) | 26.10 | Sell |
| ATR (14) | 0.19 | Info |
The 30-day technical picture shows neutral sentiment. The RSI(14) is 20, and the 50-day simple moving average is $2.43 while the 200-day simple moving average is $4.46. Price support is listed at $0.40 and resistance at $3.57.
The 30-day price range spans from $0.187 to $0.8555, indicating a relatively wide swing for a low-priced stock. Annualized volatility sits at 200%, pointing to elevated near-term risk and swing potential.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.40 | $0.425 | $0.5713 | 0% | Neutral | |
| $0.4064 | $0.5578 | $0.8272 | +31% | Bullish | |
| $0.385 | $0.5619 | $0.8891 | +32% | Bullish | |
| $0.3258 | $0.5011 | $0.8331 | +18% | Neutral | |
| $0.2662 | $0.4293 | $0.7433 | +1% | Neutral | |
| $0.2798 | $0.4717 | $0.8457 | +11% | Neutral | |
| $0.294 | $0.5171 | $0.9561 | +22% | Bullish | |
| $0.3361 | $0.6156 | $1.17 | +45% | Bullish | |
| $0.3785 | $0.7212 | $1.41 | +70% | Bullish | |
| $0.3163 | $0.6265 | $1.25 | +47% | Bullish | |
| $0.4283 | $0.9517 | $2.09 | +124% | Bullish | |
| $0.5764 | $1.28 | $2.95 | +201% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.40 | $0.425 | $0.4975 | +0.00% |
| September 2026 | $0.3249 | $0.3949 | $0.5008 | -7.08% |
| October 2026 | $0.3487 | $0.4298 | $0.5562 | +8.83% |
| November 2026 | $0.354 | $0.4413 | $0.5803 | +2.68% |
| December 2026 | $0.3399 | $0.4282 | $0.5713 | -2.97% |
Click any year to see its month-by-month MBRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect MBRX to range from $0.40 to $0.5713 through 2026. The $0.425 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The MBRX price prediction for 2027 points to an average of $0.5578 (low $0.4064, high $0.8272) — a potential gain of +31% on today's $0.425. Buyers look set to stay in control over this stretch.
In 2028, MBRX is projected to trade between $0.385 and $0.8891, averaging $0.5619 — a potential gain of +32% from today's $0.425. That is up +1% on the projected 2027 average. Momentum favours further upside here.
Moleculin Biotech, Inc.'s 2029 outlook centres on $0.5011, within a $0.3258 to $0.8331 range. That is -11% versus the projected 2028 average. That marks a +18% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, MBRX could reach as high as $0.7433, with a base case around $0.4293 and support toward $0.2662 — roughly +1% from $0.425. Price action looks broadly range-bound.
Expect MBRX to range from $0.2798 to $0.8457 through 2031. The $0.4717 average target implies a +11% move from current prices. That is up +10% on the projected 2030 average. A consolidation phase looks the most probable path here.
The MBRX price prediction for 2032 points to an average of $0.5171 (low $0.294, high $0.9561) — a potential gain of +22% on today's $0.425. Momentum favours further upside here.
In 2033, MBRX is projected to trade between $0.3361 and $1.17, averaging $0.6156 — a potential gain of +45% from today's $0.425. That is up +19% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Moleculin Biotech, Inc.'s 2034 outlook centres on $0.7212, within a $0.3785 to $1.41 range. That is up +17% on the projected 2033 average. That marks a +70% change versus current levels. Momentum favours further upside here.
By 2035, MBRX could reach as high as $1.25, with a base case around $0.6265 and support toward $0.3163 — roughly +47% from $0.425. Buyers look set to stay in control over this stretch.
Expect MBRX to range from $0.4283 to $2.09 through 2040. The $0.9517 average target implies a +124% move from current prices. That is up +52% on the projected 2035 average. Momentum favours further upside here.
The MBRX price prediction for 2050 points to an average of $1.28 (low $0.5764, high $2.95) — a potential gain of +201% on today's $0.425. Buyers look set to stay in control over this stretch.
Investing $1,000 in MBRX today (≈ 2,352.941176 MBRX) could be worth
$3,014.03
+$2,014.03 (+201%) by 2050 · US Dollar
Based on the average projected MBRX price of $1.28 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MBRXwould be worth at today's price.
$1,000 invested in MBRX on Jul 31, 2025 (≈ 63.694268 MBRX) would be worth
$27.07
-$972.93 (-97.3%) today · 0.03× · US Dollar
Based on a MBRX entry price of $15.7 vs. today's $0.425.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.12 | $200.47 | -80.0% |
| 1 month ago | $2.69 | $157.99 | -84.2% |
| 3 months ago | $2.51 | $169.32 | -83.1% |
| 6 months ago | $4.12 | $103.16 | -89.7% |
| 1 year ago | $15.7 | $27.07 | -97.3% |
| All time (5.0y) ago | $1,155 | $0.37 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MBRX forecast.
Our base-case forecast reaches $0.85 around 2040.
Implied market cap at $0.85: $6.01M
The multi-year forecast presents a path of gradual, uneven appreciation with several bullish inflections. In 2027 the avg price is $0.5267 with a max of $0.7813 and a min of $0.3837, yielding a 31.7% ROI and a bullish sentiment. The 2028 view remains bullish with an avg of $0.5277, a max of $0.8352, a min of $0.3615 and a 31.9% ROI.
For 2029 the avg drops to $0.4711, the max to $0.7833, the min to $0.3062, and the ROI is 17.8% with neutral sentiment. In 2030 the avg is $0.4056, the max $0.7023, the min $0.2514, and ROI 1.4% with neutral sentiment. The 2031–2035 window shows gradual gains and higher ROIs, with 2031 ROI 10.8% (avg $0.4432), 2032 ROI 21.6% (avg $0.4866), 2033 ROI 45.2% (avg $0.5808), 2034 ROI 69.6% (avg $0.6784), and 2035 ROI 47.4% (avg $0.5896).
The long horizon strengthens in 2040, with an avg $0.8945, a max $1.96, a min $0.4025 and a 123.6% ROI, signaling a bullish trend. The final stated year, 2050, shows an avg price of $1.21, a max of $2.78, a min of $0.5432 and a 201.8% ROI, continuing the bullish outlook. Drivers include upside in later years despite earlier flatness or modest gains, while risks include the volatility and small-cap nature of the asset, which can yield material downside in shorter horizons.
These figures are estimates and not guarantees; actual outcomes may vary widely.
Tap a question to reveal the answer.
In 2027, the forecast shows a min of $0.3837, an avg of $0.5267, and a max of $0.7813, with a 31.7% ROI and a bullish sentiment.
The forecast includes years with positive ROIs, such as 31.7% in 2027 and 31.9% in 2028, and peaks at 123.6% in 2040 and 201.8% in 2050, though some years show more modest gains (e.g., 0% in 2026 and 1.4% in 2030). Sentiment shifts from neutral to bullish across several years, highlighting potential upside tempered by risk.
Yes, the max forecast prices reach or exceed $1 in multiple years: 2033 max $1.10, 2034 max $1.32, 2040 max $1.96, and 2050 max $2.78.
The current price is $0.40 and the market cap is $2.83M.
The 30-day technical picture shows NEUTRAL sentiment with RSI(14) at 20, SMA50 at $2.43, SMA200 at $4.46, support at $0.40, and resistance at $3.57. The 30-day range runs from $0.187 to $0.8555, and annualized volatility is 200%.
Moleculin Biotech, Inc. Community Discussion
0Share your Moleculin Biotech, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.